Hair Loss Treatments Research – nicehair.org
Menu

Category Archives: Hair Loss Treatments Research

Rinvoq (Upadacitinib) for Severe Alopecia Areata: Landmark Phase 3 UP-AA Trials in JAMA Dermatology Reveal Rapid Hair Regrowth Across Scalp, Eyebrows, and Eyelashes in Adults and Teens

In double-blind, randomized Phase 3 clinical trial findings published in JAMA Dermatology and discussed across the European Academy of Dermatology and Venereology (EADV) Congress, researchers published efficacy and safety data from two parallel global Phase 3 trials (UP-AA1 and UP-AA2, ClinicalTrials.gov Identifier: NCT06012240) evaluating the selective oral Janus kinase-1 (JAK1) inhibitor upadacitinib.

Cinainu (LH-8) Topical Solution: FDA Grants Breakthrough Therapy Status to First-in-Class Multi-Plant Botanical Drug for Alopecia Areata in Adults and Children Aged 2 and Up

In a regulatory and clinical milestone announced on October 13, 2026, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Cinainu (LH-8), an investigational topical botanical solution developed by Legacy Healthcare for moderate-to-severe alopecia areata. For years, patients with autoimmune hair loss—particularly children, adolescents, and those with moderate disease—have faced severe treatment gaps.

Extended-Release Minoxidil (VDPHL01) Phase 3 Trial Meets All Endpoints: How a New Once-Daily Pill Delivers Rapid Hair Growth by Month 2 with Zero Heart Rate Spikes

In pivotal Phase 3 topline clinical data released from the multicentre Study 304 (ClinicalTrials.gov Identifier: NCT06972264), clinical trial investigators announced that VDPHL01—an investigational once-daily extended-release oral minoxidil tablet—has successfully met all co-primary and secondary efficacy endpoints in male pattern hair loss.

HCW9302 Alopecia Areata Injection: Single-Dose Regulatory T-Cell Activator Restores Immune Balance to Stop Sudden Hair Loss Without Whole-Body Immunosuppression

In late-phase clinical trial readouts and clinical updates from the multicentre Phase 1 human trial (ClinicalTrials.gov Identifier: NCT07049328), clinical researchers and immunologists revealed early clinical activity for HCW9302—a first-in-class, subcutaneously injectable interleukin-2 (IL-2) fusion immunotherapeutic.

Dermal Papilla Spheroid Micro-Engraftment: How Cultured 3D Cell Clusters Restore Follicular Inductive Signaling and Reverse Miniaturization in Real Research

A fundamental barrier in hair biology is that mammalian hair follicles rely on a fixed population of mesenchymal cells located at the base of the hair bulb: dermal papilla cells (DPCs).

Lab-Grown Hair Cloning: How 3D Collagen Micro-Scaffolds Sprout New Hair Follicles from Reprogrammed Stem Cells Without Depleting Donor Hair

In peer-reviewed tissue engineering research published in ACS Biomaterials Science & Engineering and translational regenerative updates featured across biotechnology forums, biomaterials scientists and stem cell biologists revealed a significant advance in bioengineering: human iPSC-derived hair follicle organoids (HFOs) assembled with low-concentration collagen I micro-scaffolds.

Autologous Dermal Papilla Cell Therapy (EPI-001): Landmark Phase 1/2a Clinical Trial Dosing Confirms Micro-Injected Hair Follicle Spheroids Rebuild Miniaturized Root Architecture Without Systemic Drug Toxicity

In late-phase clinical trial milestones and ongoing multicenter human evaluations registered under ClinicalTrials.gov Protocol NCT07618195, clinical researchers and regenerative medicine scientists at Epibiotech advanced EPI-001—an autologous cultured dermal papilla cell therapy—through active clinical patient dosing.

How NUL-5 May Keep Hair Follicles Growing: The HGF, DKK1-Wnt and Elastin Mechanism Explained

NUL-5 appears to attack follicle regression from three directions: HGF stimulates hair-matrix cells, reduced DKK1 releases Wnt signaling, and tropoelastin may reinforce the dermal papilla niche. This deep dive separates the promising human-follicle biology from what remains unproven in patients.

JW0061 GFRA1-Wnt Activator Clinical Trial Entry: First-in-Class Small Molecule Binds Dermal Papilla Receptor to Outperform Minoxidil by Over 7-Fold in Follicle Neogenesis Assays

In late-phase clinical trial regulatory filings and pipeline data confirmed by the Korea Drug Development Fund (KDDF) and JW Pharmaceutical, researchers announced the Phase 1 clinical trial entry of JW0061—a first-in-class topical small molecule designed to trigger direct follicle neogenesis by binding GFRA1.

Pelage PP405 Phase 2/3 AWAKEN Trial Dosing Milestone: First Patient Dosed as Topical Mitochondrial Pyruvate Carrier Inhibitor Advances to Awaken Dormant Hair Follicle Stem Cells in Norwood IV-V Baldness

Research ArticIn a clinical milestone announced on October 14, 2026, Pelage Pharmaceuticals officially dosed the first patient in its landmark Phase 2/3 AWAKEN registration trial (ClinicalTrials.gov Identifier: NCT07819435), advancing its topical first-in-class small molecule, PP405, into late-stage testing for androgenetic alopecia.

ABS-201 Prolactin Receptor Antibody Breakthrough: Generative AI Biologic Halts K15+ Stem Cell Apoptosis to Drive Follicle Terminalization with Zero Systemic Hormone Depletion

In translational ex vivo data presented at the Barcelona Hair Meeting and late-phase clinical updates from the randomized HEADLINE Phase 1/2a trial (ClinicalTrials.gov Identifier: NCT07317544), researchers revealed results for ABS-201—a first-in-class monoclonal antibody engineered via generative AI to block the Prolactin Receptor (PRLR).

Rubedo RLS-1496 Clinical Trial Launch: First-in-Class GPX4 Senolytic Modulator Clears Pathologic Zombie Cells from Miniaturizing Follicle Niches to Outperform Finasteride in Human Scalp Models

In clinical announcements and human ex vivo evidence released by Rubedo Life Sciences, researchers confirmed the clinical entry of RLS-1496—the world’s first-in-class GPX4 (Glutathione Peroxidase 4) senolytic modulator tested specifically for androgenetic alopecia.

NUL-5 Hair Growth Breakthrough: Human Scalp Follicles Stayed in Anagen as Tropoelastin and HGF Reactivated Wnt Signaling

A new human hair-follicle study reports that NUL-5, an experimental blend of tropoelastin and hepatocyte growth factor, prolonged anagen, increased matrix-cell proliferation and restored dermal papilla activity. Here is what the conference data really show, and why it is not yet a proven treatment for hair loss.

MNC-QQ Cell Therapy Hair Regrowth Breakthrough: First-in-Human Trial Reports 78% Terminal Hair Density Surge After One Autologous Scalp Injection Session

A first-in-human open-label study of autologous MNC-QQ cell therapy reported no adverse effects and significant 6-month gains in hair count, density, mass, thickness, and terminal hair density in five men with androgenetic alopecia.

Clascoterone 5% Solution (Breezula) Phase 3 SCALP Results: Topical Androgen Receptor Antagonist Delivers Up to 539% Relative Hair Count Surge Over Placebo with Zero Systemic Endocrine Disruption

In late-phase clinical trial readouts from the pivotal Phase 3 SCALP clinical development program (SCALP 1 and SCALP 2) conducted across 51 medical centers in the United States and Europe, dermatologists and clinical investigators revealed landmark efficacy data for clascoterone 5% topical solution (investigational code CB-03-01 / Breezula).

Sublingual Minoxidil Hair Growth Mechanism: How Under-the-Tongue Delivery May Boost Anagen Without Blocking Testosterone

Sublingual minoxidil may help testosterone-associated pattern hair loss by delivering minoxidil systemically without directly suppressing testosterone or DHT, then relying on follicular sulfotransferase activation, dermal papilla potassium-channel signaling, VEGF, and longer anagen growth.

MLPH Peptide Hair Regrowth Breakthrough: DGIST Study Reveals Erythropoietin-Derived Helix C-1 Molecule Drives IGF-1 Signaling to Elongate Human Hair Shafts with Zero Blood or Hormone Side Effects

In a bioengineering and regenerative medicine breakthrough published in the peer-reviewed medical journal Biomedicine & Pharmacotherapy, a joint research team from DGIST (Daegu Gyeongbuk Institute of Science and Technology) and Kyungpook National University School of Medicine revealed a novel synthetic peptide: MLPH.

Sublingual Minoxidil Hair Regrowth Breakthrough: Testosterone-Treated Transgender Trial Shows +15.7 Hairs/cm2 Midfrontal Gain Without Lowering Testosterone

A new JAAD randomized placebo-controlled trial reports that sublingual minoxidil improved midfrontal hair count in transgender people receiving full-dose testosterone, with no serious adverse events and no change in testosterone concentrations.

MLPH Peptide Hair Growth Mechanism: How EPOR-IGF-1 Signaling May Switch Dermal Papilla Cells Back Into Anagen Mode

MLPH is exciting because it may copy the hair-growth side of erythropoietin without the blood-building side: EPOR activation in dermal papilla cells, ERK/AKT signaling, higher IGF-1 output, longer human hair shafts, and faster anagen entry in mice.

MLPH Peptide Hair Regrowth Breakthrough: DGIST Study Reveals Erythropoietin-Derived Helix C-1 Molecule Drives IGF-1 Signaling to Elongate Human Hair Shafts with Zero Blood or Hormone Side Effects

In a bioengineering and regenerative medicine breakthrough published in the peer-reviewed medical journal Biomedicine & Pharmacotherapy, a joint research team from DGIST (Daegu Gyeongbuk Institute of Science and Technology) and Kyungpook National University School of Medicine revealed a novel synthetic peptide: MLPH.

Deuruxolitinib Hair Regrowth Dose Breakthrough: Phase 2 Trial Shows 8 mg Twice Daily Beats 16 mg Once Daily for Severe Alopecia Areata

A new Phase 2 randomized trial found that splitting deuruxolitinib into 8 mg twice daily produced much stronger scalp hair regrowth than the same 16 mg total daily dose taken once daily in adults with severe alopecia areata.

Microneedling + Minoxidil Mechanism: Why 500–550 Micrometer Needling May Be Too Shallow to Boost Female Hair Regrowth

Microneedling can theoretically boost minoxidil through drug-delivery channels and wound-healing signals, but the new 245-woman trial suggests shallow 500–550 micrometer needling may not trigger enough added follicle biology to beat minoxidil alone.

Microneedling + Minoxidil Hair Growth Reality Check: 245-Woman Trial Finds No Extra Regrowth From 500–550 Micrometer Needling Every 2 or 4 Weeks

A new randomized trial in 245 women with female androgenetic alopecia found that adding shallow 36-needle microneedling every 2 or 4 weeks did not improve hair counts beyond 2% minoxidil alone after 24 weeks.

Topical Dutasteride Hair Growth Mechanism: How Local 5-Alpha-Reductase Blockade May Cut Scalp DHT Without Crashing Systemic Hormones

Topical dutasteride may work by blocking type I and type II 5-alpha-reductase inside the scalp, reducing follicle-level DHT pressure while producing far less serum DHT suppression than oral dutasteride in the Phase II trial.

Topical Dutasteride 0.05% Hair Regrowth Breakthrough: Phase II Trial Reports a 75.5 Hairs/cm2 Density Surge Without the Usual Systemic DHT Crash

A new Phase II randomized trial suggests a novel 0.05% topical dutasteride solution may sharply increase target-area hair count in male pattern hair loss while producing far less systemic DHT suppression than oral dutasteride.

CXCL12–CXCR4 Chemokine Axis in Hair Loss: Groundbreaking Study Reveals How Dihydrotestosterone Hijacks Dermal Fibroblasts to Trigger Inflammatory Follicular Miniaturization Beyond Androgen Receptors Alone

In multi-center investigations and molecular spatial profiling published across peer-reviewed dermatological and immunological journals, researchers uncovered a missing link driving genetic pattern baldness: the fibroblast-derived CXCL12–CXCR4 chemokine axis.

CXCL12–CXCR4 Chemokine Pathway in Hair Loss: How Dihydrotestosterone Reprograms Dermal Fibroblasts to Induce Microenvironmental Miniaturization in Real Research

A major shift in follicular biology moved understanding past the traditional “DHT-only” model of androgenetic alopecia (AGA). Spatial transcriptomics, single-cell RNA sequencing, and human hair organ cultures demonstrated that pattern baldness is not solely a disorder of direct androgen receptor binding inside dermal papilla cells. Instead, dihydrotestosterone (DHT) triggers a secondary, non-hormonal microenvironmental cascade driven by the CXCL12–CXCR4 chemokine axis.

DKK-1 siRNA Hair Growth Mechanism: How CosmeRNA-DKK1 May Release the Wnt/Beta-Catenin Brake That Miniaturizes Follicles

CosmeRNA-DKK1 targets one of the follicle’s most important growth brakes: DKK-1. By silencing this Wnt-blocking signal, topical siRNA may help miniaturized follicles regain stronger dermal papilla, stem-cell, and anagen-growth communication.

Topical DKK-1 siRNA Hair Regrowth Breakthrough: New CosmeRNA-DKK1 Trial Targets the Wnt “Off Switch” Behind Follicle Miniaturization

A new JAAD ahead-of-print randomized trial reports that a topical siRNA formula targeting DKK-1, a Wnt-blocking signal linked to androgen-driven follicle miniaturization, may improve hair density in mild-to-moderate androgenetic alopecia without directly altering systemic hormones.

Latanoprost Acid Hair Growth Mechanism: How FP-Receptor Calcium Signaling May Reawaken Dermal Papilla Cells and Reverse Follicle Miniaturization

Latanoprost acid may boost hair growth by directly activating prostaglandin F2-alpha receptors in the dermal papilla, triggering calcium signals that push miniaturized follicles back toward anagen, multi-hair output, and thicker visible density.